40 mg, 80 mg tablets
Angiotensin II receptor (type AT1) antagonist. Selectively blocks the binding of angiotensin II to the AT1 receptors in many tissues (e.g., vascular smooth muscles, adrenal glands). Blocks the vasoconstricting and aldosterone-secreting
effects of angiotensin II, thus resulting in an antihypertensive effect.
Effectiveness is indicated by a reduction in BP.
Treatment of hypertension.
Hypersensitivity to telmisartan or other angiotensin receptor antagonists (e.g., losartan, eprosartan, etc.); pregnancy
(category C first trimester; category D second and third trimester), lactation.
Coronary artery disease (CAD); hypertropic cardiomyopathy; CHF; oliguria; hypotension; renal artery stenosis; older adult
patients; biliary obstruction; liver dysfunction; renal impairment. Safety and efficacy in children <18 y are not established.
Route & Dosage
Adult: PO 40 mg q.d., may increase to 80 mg/d
- Do not remove tablets from blister pack until immediately before administration.
- Correct volume depletion prior to initial dose.
- Store at 15°30° C (59°86° F).
Adverse Effects (≥1%)Body as a Whole:
Back pain, flu-like syndrome, myalgia, headache, fatigue
Hypotension, hypertension, chest pain, peripheral edema. GI:
Diarrhea, dyspepsia, abdominal pain, nausea. Respiratory: Sinusitis
may increase digoxin
Absorption is dose dependent, 42% of 40 mg dose is absorbed. Peak:
0.51 h. Distribution:
>99% protein bound. Metabolism:
Minimally metabolized. Elimination:
Primarily in feces as unchanged drug. Half-Life:
Assessment & Drug Effects
- Monitor BP carefully after initial dose; and periodically thereafter. Monitor more frequently with preexisting biliary obstructive
disorders or hepatic insufficiency.
- Monitor dialysis patients closely for orthostatic hypotension.
- Lab tests: Periodic Hgb, creatinine clearance, liver enzymes.
- Monitor concomitant digoxin levels throughout therapy.
Patient & Family Education
- Report pregnancy to physician immediately.
- Allow between 24 wk for maximum therapeutic response.